Blue Jays and Astros Discuss Varsho for Arrighetti Swap, With Medical Reviews Ongoing

The Toronto Blue Jays and Houston Astros are nearing a trade that would send center fielder Daulton Varsho to Houston in exchange for starting pitcher Spencer Arrighetti, according to a report from Mitch Bannon of The Athletic as carried by MLB Trade Rumors. As of Tuesday, the deal is not presented as complete, and the two organizations are reportedly in the final stages of evaluation, including a review of medical records for both players.

For Toronto, Varsho’s profile has long fit the type of addition teams look for when they want an everyday defender with versatility and athleticism. The reported direction of this swap suggests the Blue Jays could be prioritizing pitching depth and starting-lineup upside, particularly from the right side, as they evaluate how best to reshape their roster. For Houston, Arrighetti’s inclusion indicates a continued interest in acquiring starting pitching that can stabilize rotation innings. Arrighetti’s role as a right-handed starter in this framework is the core of what the Astros are reportedly seeking, a natural match for a team that often places emphasis on run-prevention and consistent innings from its rotation. The key detail in the current reporting is the medical-record process. MLB Trade Rumors reported that both teams are reviewing the players’ medical records as part of the trade process. That step is common in high-stakes deadline or near-deadline conversations, but it also serves as a reminder that even well-advanced discussions can stall if a concern shows up in the review.

In these situations, teams typically use the medical evaluation to confirm that a player’s health status aligns with what the club expected based on prior examinations, treatment history, and performance availability. The current reporting does not specify any medical findings or injury status. Instead, it places the emphasis on the standard due-diligence step: both clubs are checking the information before agreeing to final terms.

Because the report is framed as “near” rather than completed, roster timing and final structure remain unknown. Trades of this type can involve additional considerations beyond the two players at the center, including how long the teams believe the receiving player can contribute and whether the other side’s needs change after the initial evaluation. Until the teams provide an official transaction announcement, the safe assumption is that the medical review is a gating item.

It is also worth noting what this kind of swap implies about organizational planning. Varsho, as a position player with established day-to-day defensive value, represents a relatively direct exchange for a pitcher who can be part of the rotation’s longer arc. For the Astros and Blue Jays, the reported framework suggests each side is trying to address a specific roster priority, with one organization leaning toward position-player impact and the other toward starting pitching depth.

What to watch next is simple: whether the medical review clears and the clubs proceed to announce the trade. If it does, it will likely reshape how both teams manage their rotation workload and outfield alignment, while also revealing how each front office is balancing present competitiveness with longer-term roster construction. If the talks stall at the medical stage, the two teams could continue to negotiate around alternative structures or other targets.